CBD from cannabis causes lethargy

Cannabis use with consequences

literature

[1] United Nations Office on Drugs and Crime: World Drug Report 2014 (United Nations publication, Sales No. E.14.XI.7)

[2] Drugs and Addiction Report of the Federal Government 2018 - The Drug Commissioner of the Federal Government, Federal Ministry of Health. www.drogenbeauftragte.de/fileadmin/daten-dba/Drogenbeauftragte/Drogen_und_Suchtbericht/pdf/DSB-2018.pdf

[3] Gloss D. An overview of products and bias in research. Neurotherapeutics 2015. 12 (4): 731-734

[4] Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964; 86: 1646-1647

[5] Iversen L. The science of marijuana, second edition. 2007; Oxford: Oxford University Press

[6] European Monitoring Center for Drugs and Drug Addiction: Drugs Supply in Europe (EMCDDA). In: European Drugs Report 2014: Trends and Developments. Luxembourg: Publications Office of the European Union 2014

[7] Cascini F, Aiello C, Di Tanna G. Increasing delta-9-tetrahydrocannabinol (Delta-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 2012; 5: 32-40

[8] Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol 2012; 2: 241-254

[9] Englund A, Morrison PD, Nottage J et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 2013; 27: 19-27

[10] Bhattacharyya S, Wilson R, Appiah-Kusi E et al. Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial. JAMA Psychiatry. 2018; 75 (11): 1107-1117

[11] Kuepper R, Morrison PD, van Os J et al. Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophr Res 2010; 121 (1): 107-117

[12] Howes OD, Kambeitz J, Kim E et al. The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment: Meta-analysis of Imaging Studies. Arch Gen Psychiatry 2012; (Epub ahead of print)

[13] Dean B, Sundram S, Bradbury R et al. Studies on [3H] CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001; 1031: 9-15

[14] Zavitsanou K, Garrick T, Huang XF. Selective antagonist [H-3] SR141716A binding to cannabinoid CB1-receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuro-Psychoph 2004; 28: 355-360

[15] WHO. The health and social effects of nonmedical cannabis use. 2016, www.who.int/substance_abuse/publications/msbcannabis.pdf

[16] Töppich J. Cannabis use by adolescents. In: Jugendkult Cannabis - Risks and Help. Documentation of the conference on November 29th and 30th, 2004 in the Federal Ministry for Health and Social Security, Berlin

[17] Petersen KU, Thomasius R. Effects of cannabis use and abuse. Expertise on health and psychosocial consequences. A systematic review of the internationally published studies from 1996 to 2006. Lengerich: Pabst 2007

[18] Effertz T, Verheyen F, Linder R. Economic and intangible costs of cannabis use in Germany. SEEK 2016; 62.31-41

[19] Hoch E, Bonnet U, Thomasius R et al. Risks associated with the non-medicinal use of cannabis. Dtsch Arztebl Int. 2015; 112: 271-278

[20] Bonnet U, Scherbaum N. Cannabis-related disorders. Part II: Psychiatric and somatic sequelae and comorbidities. Fortschr Neurol Psychiat. 2010; 78: 1-11

[21] Thomasius R, Weymann N, Stolle M et al. Cannabis use and abuse in adolescents and young adults. Effects, comorbidity and therapeutic aids. Psychotherapist 2009; 54: 170-178

[22] Danielsson AK, Falkstedt D, Hemmingsson T et al. Cannabis use among Swedish men in adolescence and the risk of adverse life course outcomes: results from a 20 year follow-up study. Addiction 2015; 10 (11): 1794-1802

[23] Fergusson DM, Horwood LJ, Beautrais AL. Cannabis and educational achievement. Addiction 2003; 98 (12): 1681-1692

[24] Thomasius R. The consequences of regular consumption are often underestimated. NEUROLOGIE & PSYCHIATRIE 2005; 7 (6), CME training in psychiatry

[25] Degenhardt L, Ferrari AJ, Calabria B et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 Study. PLoS One 2013; 8 (10): e76635

[26] Morrison PD, Zois V, McKeown DA et al. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 2009; 3910: 1607-16

[27] 27 Solowij N. Cannabis and Cognitive Functioning. Cambridge: Cambridge University Press; 1998

[28] Ranganathan M, D’Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology 2006; 188: 425-444

[29] Stolle M, Sack PM, Thomasius R. Drug use in childhood and adolescence. Deutsches Ärzteblatt 2017; Volume 104, 28–9

[30] Lorenzetti V, Lubman DI, Whittle S et al. Structural MRI findings in longterm cannabis users: what do we know? Subst Use Misuse 2010; 45 (11): 1787-1808

[31] Yucel M, Zalesky A, Takagi MJ et al. White-matter abnormalities in adolescents with long-term inhalant and cannabis use: a diffusion magnetic resonance imaging study. J Psychiatry Neurosci 2010; 35 (6): 409-412

[32] Fergusson DM, Horwood LJ, Ridder EM. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 2005; 100: 354-366

[33] Arseneault L, Cannon M, Witton J et al. Causal association between cannabis and psychosis: examination of the evidence. Brit J Psychiat 2004; 184: 110-117

[34] Zammit S, Allebeck P, Andreasson S et al. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002; 325 (7374): 1199

[35] Smith DE. Acute and Chronic Toxicity of Marijuana. J Psychedel Drug 1968; 2: 37-47

[36] Talamo A, Centorrino F, Tondo L, et al. Comorbid substance-use in schizophrenia: relation to positive and negative symptoms. Schizophr Res 2006; 86: 251-255

[37] Martin-Santos R, Fagundo AB, Crippa JA et al. Neuroimaging in cannabis use: a systematic review of the literature. Psychol Med 2010; 40: 383-398

[38] Hermann D. Current neurobiological studies on the health consequences of cannabis use with a focus on psychoses and neuropsychological deficits. In: 2nd Alternative Drugs and Addiction Report 2015

[39] Grech A, Van Os J, Jones PB et al. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry 2005; 20 (4): 349-353

[40] Orr C, Spechler C, Zhipeng C, et al. Journal of Neuroscience, January 14, 2019, 3375-3317; DOI: 10.1523 / JNEUROSCI.3375-17.2018